Bosera Hang Seng Health Care ETF(QDII)

JD Health spends 93.26 million HKD to repurchase 2.25 million ordinary shares on May 19

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

JD Health and AliHealth stocks fall on GLP-1 regulatory concerns, brokers call overreaction

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

JD Health spends 8.9453 million HKD to repurchase 198,100 shares on May 15

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

CSC Financial Maintains Buy Rating on JD Health International with Target Price of 58.28 HKD

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

Nomura lowers JD Health target price to HKD 67, maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

159849

512010

159992

513700

159892

ARKG

159837

513060

516500

512290

520500

Relay Therapeutics has launched a public offering of $175 million in common stock, with all shares sold by the company. Underwriters have a 30-day option to purchase an additional 15% of shares. Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities are the joint bookrunners. The offering is subject to market conditions.

PUBT

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Direxion S&P Biotech Bull 3X

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares Biotechnology ETF

VG Health

iShares Global Healthcare

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

E Fund CSI Biotechnology Theme ETF

Proshares Ultra Nasdaq Biotech

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Guotai CSI Bio-medicine ETF

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ALPS Medical Breakthrough

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

VanEck Biotech ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Relay Therapeutics

Jefferies Financial

Goldman Sachs

GS Hldg R

Relay Therapeutics launches $175 million common stock offering

159859

Ipsen announced findings from the Phase IV DIRECTION trial comparing Dysport and Botox for upper limb spasticity. The results, presented at the ISPRM congress in Vancouver on May 19, 2026, showed Dysport had a similar safety profile to Botox and offered longer-lasting symptom relief.

Unusual Whales

Tianhong CNI BIOMEDICINE ETF

Proshares UltraShort Nasdaq Biotech

China Southern Hang Seng Biotech ETF(QDII)

Invesco Nasdaq Biotechnology ETF

BlackRock, Inc.

Penghua SSE STAR Biology and Medicine ETF

SPDR S&P Biotech

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

benzinga_article

United States Oil Fund LP

Spdr Select Indu

ProShares Ultra Energy

SPDR S&P Software

iShares US Oil Equip & Svcs

SPDR Energy Select

Pro Ultr Bloomberg Crude Oil

SPDR O&G Ex & Prd

VG Energy

iShares US Medical Devices

ISHRS S&P Glb Engy

iShares Expanded Tech Software Sector ETF

SPDR S&P Health Equip

China Merchants CSI All Share Medical Apparatus and Instruments ETF

VanEck Oil Services ETF

Spdr Select Tech

SPDR FD Consumer Discretionary

Spdr Material

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Financial Select Sector SPDR Fund

SPDR FD Consumer Staples

Leading And Lagging Sectors For May 19, 2026

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

Tip Ranks

REMEGEN

RemeGen

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

02268

WXXWY

02269

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Microbiotica reports positive results for MB097 in advanced melanoma

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera reports promising tinengotinib results in advanced solid tumors

603259

WUXI APPTEC plans to issue RMB6.78 billion in zero-coupon convertible bonds due 2027, with an initial conversion price of HKD153 per H share. This represents a 17.6% premium over the previous closing price. The bonds may convert into approximately 51.147 million H shares, accounting for about 9.11% of the enlarged H share capital. Estimated net proceeds are around USD1.023 billion, with 90% allocated for global expansion and 10% for general corporate purposes.

AASTOCKS News

WuXi AppTec

WUXI APPTEC

WUXI APPTEC  Plans to Issue RMB6.78B Convertible Bonds

Ring Therapeutics®, a biotech firm based in Cambridge, Massachusetts, disclosed fresh insights on its Vector Conjugate system and VectorBricks™ in vitro manufacturing technology. The company unveiled this data on May 14, 2026. The innovative platform aims to develop precise medications.

Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

Bosera Hang Seng Health Care ETF(QDII)(513060.SH)